GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Pharmaceutical

GNI Group

Ying Luo

Thomas Eastling

GNI Group's Leadership Team includes Ying Luo and 1 others.

Leadership Team

About

Team members

Other teams at GNI Group

Board of Directors

CEO and Executive Team